Carbetocin

Carbetocin binds oxytocin receptors (OTRs), which are Gq-coupled GPCRs. OTR activation in uterine smooth muscle activates PLC-beta, generating IP3 and DAG. IP3 releases Ca2+ from the sarcoplasmic reticulum, and DAG activates PKC, causing actin-myosin cross-bridge formation and uterine contraction. The uterotonic effect reduces postpartum uterine bleeding by contracting the myometrium and mechanically compressing bleeding sinusoids. Carbetocin's structural modifications increase receptor binding duration and slow dissociation, explaining its prolonged uterotonic action.

Like oxytocin, carbetocin crosses the blood-brain barrier to some extent and activates central OTRs in the amygdala, hypothalamus, and limbic system. Central OTR activation mediates the anxiolytic, trust-enhancing, and prosocial effects attributed to oxytocin. Carbetocin's longer half-life may produce more sustained central effects than native oxytocin, making it a research tool for studying oxytocin receptor pharmacology in behavior. Central carbetocin reduces anxiety-like behavior in animal models and promotes social approach.

Carbetocin has higher selectivity for OTR over vasopressin V1a, V1b, and V2 receptors compared to native oxytocin, reducing pressor and antidiuretic side effects. It is resistant to proteolytic degradation by oxytocinases and aminopeptidases due to its structural modifications (deamination and O-methyl group). The room-temperature stability (24+ months at 25 C) is a major practical advantage over oxytocin (which requires cold chain refrigeration), especially for WHO FIGO guidelines on PPH prevention in low-resource settings.

The CHAMPION trial (n=29,645 women in 10 countries) demonstrated carbetocin 100 mcg IV/IM is non-inferior to oxytocin 10 IU for PPH prevention at cesarean section. Additional blood loss, uterotonic drug use, and transfusion rates were comparable. The room-temperature stable formulation (Carbetocin WHO, Ferring) received WHO prequalification in 2020, enabling global distribution without cold chain requirements. This makes carbetocin the preferred agent in low-resource settings.

Carbetocin is being studied as a long-acting oxytocin receptor agonist for anxiety disorders, social anxiety, PTSD, and autism spectrum disorder (ASD). Its longer duration (vs intranasal oxytocin) may provide more consistent OTR occupancy relevant to social behavior modification. Animal studies show carbetocin improves social recognition memory, reduces social anxiety, and promotes affiliative behavior, effects shared with intranasal oxytocin but more sustained.

Oxytocin receptor signaling regulates food reward and eating behavior, OTR activation reduces binge eating, sweet preference, and emotional eating in preclinical models. Carbetocin reduces compulsive eating and caloric intake in obese and binge-eating rat models. Pilot human studies of intranasal oxytocin have shown reductions in caloric intake and improved body image in anorexia nervosa, suggesting carbetocin's longer action could be beneficial in eating disorder pharmacotherapy.